IR-Med 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Ran Ziskind

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	3.6yrs
이사회 평균 재임 기간	3.9yrs

최근 관리 업데이트

Recent updates

CEO

Ran Ziskind

less than a year

테뉴어

Mr. Ran Ziskind is Chief Executive Officer of IR-Med Inc. from September 1, 2024. Mr. Ziskind is a highly experienced high-tech innovator and company leader with two decades of expertise in launching, deve...

리더십 팀

이름	위치	테뉴어	보상	소유권
Oded Bashan	Co-Founder & Chairman	11.2yrs	US$273.73k	12.13% $ 7.1m
Aharon Klein	Co-Founder	11.2yrs	US$101.07k	11.07% $ 6.5m
Aharon Binur	Chief Development Officer	3.6yrs	US$252.67k	0% $ 0
Ran Ziskind	Chief Executive Officer	less than a year	데이터 없음	데이터 없음
Yaniv Cohen	Co-Founder	1.8yrs	데이터 없음	11.07% $ 6.5m
Sharon Levkoviz	CFO, Treasurer & Secretary	3.9yrs	데이터 없음	0% $ 0
Avi Vachnis	Head of Software & AI	3.3yrs	데이터 없음	데이터 없음

3.6yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 관리: IRME 의 관리팀은 경험 ( 3.6 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Oded Bashan	Co-Founder & Chairman	11.2yrs	US$273.73k	12.13% $ 7.1m
Aharon Klein	Co-Founder	11.2yrs	US$101.07k	11.07% $ 6.5m
Yaniv Cohen	Co-Founder	3.9yrs	데이터 없음	11.07% $ 6.5m
Ohad Bashan	Director	3.9yrs	데이터 없음	0% $ 0
Richard Serbin	Member of Advisory Board	1.2yrs	데이터 없음	데이터 없음
Ron Mayron	Independent Director	3.9yrs	US$78.50k	0% $ 0
David Levy	Director of IR-Med Ltd	9.8yrs	데이터 없음	데이터 없음
Lynn Eschenbacher	Member of Advisory Board	no data	데이터 없음	데이터 없음
Avital Rosenberg	Independent Director	less than a year	데이터 없음	데이터 없음

3.9yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 이사회: IRME 의 이사회는 경험(평균 재직 기간 3.9 년)으로 간주됩니다.

IR-Med 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

IR-Med Inc. Announces Chief Executive Officer Changes

IR-Med Inc. Appoints Avital Rosenberg as A Class I Director and Member of the Audit Committee

IR-Med Inc., Annual General Meeting, Nov 07, 2023

IR-MED Announces Executive Changes Effective as of October 15, 2023

IR-Med Inc. Appoints Richard Serbin, Esq. to Its Advisory Board

IR-Med Inc. Appoints Lynn Eschenbacher to its Advisory Board

Recent updates

IR-Med Inc. Announces Chief Executive Officer Changes

IR-Med Inc. Receives $500,000 Grant from the Israel Innovation Authority to Develop its Platform Technology for the Early Detection of Diabetic Foot Ulcers

IR-Med Inc. has filed an IPO in the amount of $8 million.

IR-Med Inc. Appoints Avital Rosenberg as A Class I Director and Member of the Audit Committee

IR-Med Inc.’s PressureSafe Reduced Pressure Injuries by 50% During a Usability Study with Clalit, Israel’s Hmo

IR-Med Inc.'S PressureSafe Receives FDA Listing for the Indication of Decision Support Device for Pressure Injuries

IR-MED to Report New Clinical Efficacy Data for Detection of Pressure Injuries with its AI- Based PressureSafe™ Device at NPIAP 2024 Annual Conference on February 16

IR-Med Inc., Annual General Meeting, Nov 07, 2023

IR-MED Announces Executive Changes Effective as of October 15, 2023

Ir-Med to Conduct Usability Study with Methodist Healthcare of San Antonio for Its Pressuresafe Device Which Is Slated for U.S. Launch in H1 2024

IR-Med Inc. Appoints Richard Serbin, Esq. to Its Advisory Board

Ir-Med Inc. Announces Interim Results from A Clinical Study of Pressuresafe

IR-Med Inc. Appoints Lynn Eschenbacher to its Advisory Board

IR-Med Inc., Annual General Meeting, Dec 12, 2022

IR-Med Announces Appointment of Moshe Gerber as Chief Executive Officer

International Display Advertising, Inc. (OTCPK:IDAD.D) completed the acquisition of IR Med, Ltd.

International Display Advertising, Inc. announced that it expects to receive $5 million in funding

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령